Back to results
US 2019/0170731 A1Published application
Method to measure relative utilization of aerobic glycolysis by positional isotopic discrimination
OwnerDa-Qing YANG, Adrian HEGEMAN +2inventors
InventorsDa-Qing YANG, Adrian HEGEMAN, Dana FREUND, Margot CLEARY
Life of this patent
Estimating the term…
Abstract
Methods to detect aerobic glycolysis that employ isotopically labelled glucose are provided.
Claims23
A method to detect aerobic glycolysis in a sample comprising cells, comprising:
- a) providing a mixture comprising a sample obtained from mammalian cells and isotopically labelled glucose;
- b) measuring in the mixture the conversion of isotopically labelled glucose to isotopically labelled lactate using liquid chromatography-mass spectrometry (LC-MS) or;
- and
- c) determining glucose uptake, lactate concentration or the rate of aerobic glycolysis in the cells in the sample based on the presence or amount of the labelled lactate, the rate of conversion of the labelled glucose to the labelled lactate, in the mixture, or comparing the amount of converted lactate to the amount of converted lactate in corresponding cells.
1 more element
5-6. (canceled)
8-11. (canceled)
13-32. (canceled)
A method to monitor cancer recurrence in a mammal, comprising:
- a) providing a mixture comprising a sample from the mammal treated for cancer comprising cells and an amount of 13C or deuterium labelled glucose;
- b) measuring in the mixture the conversion of the 13C or deuterium labelled glucose to 13C or deuterium labelled lactate using LC-MS;
- and
- c) determining whether the mammal is at risk of recurrence based on the presence or amount of the 13C or deuterium labelled lactate, or the rate of conversion of the 13C or deuterium labelled glucose to 13C or deuterium labelled lactate, in the mixture.
1 more element
A method to monitor a therapeutic response to a cancer therapy in a mammal having cancer, comprising:
- a) providing a mixture comprising a sample from the mammal comprising cells and an amount of 13C or deuterium labelled glucose;
- b) measuring in the mixture the conversion of the 13C or deuterium labelled glucose to 13C or deuterium labelled lactate using LC-MS;
- and
- c) determining whether the mammal has a therapeutic response to the therapy based on the presence or amount of the 13C or deuterium labelled lactate, or the rate of conversion of the 13C or deuterium labelled glucose to 13C or deuterium labelled lactate, in the mixture.
1 more element
Dependencies are inferred from the claim text.